SIENA, Italy, January 23, 2019 /PRNewswire/ --
Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Novartis to discover and develop a new class of immunomodulatory therapeutics.
"We are extremely pleased to establish a new collaboration with Novartis, a leader in the discovery and development of therapies for cancer patients," commented Dr. Duccio Neri, Philogen's CEO.
No financial details of the agreement were released.
Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit http://www.philogen.com.
SOURCE Philogen S.p.A